FDA Drug Shortage Database
Liraglutide (Victoza) shortage
The FDA Drug Shortage Database lists 3 of 11 liraglutide presentations as limited or unavailable (updated September 22, 2026); the first entry was posted on July 18, 2023. 6 more presentations are on the list as available.
- Generic listed
- In shortage
- Boxed warning
Check it at the source: the FDA Drug Shortage Database.
Which strengths are short?
| Strength | Limited or unavailable now | Listed now, available | Resolved or discontinued |
|---|---|---|---|
| 6mg/1ml injection | 3 | 6 | 2 |
Which presentations are listed?
Limited or unavailable now (3)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | Novo Nordisk, Inc. | Current posted July 18, 2023, updated September 22, 2026 | Limited Availability; Discontinuation of the manufacture of the drug |
| Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12) | Novo Nordisk, Inc. | Current posted July 18, 2023, updated September 22, 2026 | Limited Availability; Delay in shipping of the drug |
| Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13) | Novo Nordisk, Inc. | Current posted July 18, 2023, updated September 22, 2026 | Limited Availability; Delay in shipping of the drug |
Listed now, available (6)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) | Hikma Pharmaceuticals USA, Inc. | Current posted July 18, 2023, updated September 18, 2026 | Available |
| Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) | Hikma Pharmaceuticals USA, Inc. | Current posted July 18, 2023, updated September 18, 2026 | Available |
| Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) | Novo Nordisk, Inc. | Current posted July 18, 2023, updated September 22, 2026 | Available |
| Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) | Novo Nordisk, Inc. | Current posted July 18, 2023, updated September 22, 2026 | Available |
| Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84) | Meitheal Pharmaceuticals, Inc. | Current posted July 18, 2023, updated August 27, 2026 | Available |
| Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85) | Meitheal Pharmaceuticals, Inc. | Current posted July 18, 2023, updated August 27, 2026 | Available |
Resolved or discontinued (2)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued posted May 14, 2026, updated May 14, 2026 | not given |
| Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | Novo Nordisk, Inc. | To Be Discontinued posted August 25, 2026, updated August 25, 2026 | not given |
Source: FDA Drug Shortage Database via openFDA, read October 8, 2026
Are medicines for the same conditions short too?
Medicines whose labels share an indication with this one, and their own shortage status; listed as records, not substitutes.
| Medicine | Shared indication | Shortage | Generic labelers | Pharmacy cost |
|---|---|---|---|---|
| Tirzepatide | Heart attack and coronary artery disease, Type 2 diabetes, Weight management | No current entry | none listed | $538.68 per mL 10 mg/0.5 mL pen |
| Semaglutide | Heart attack and coronary artery disease, Type 2 diabetes, Weight management | A presentation being discontinued | none listed | $331.99 per mL 0.25-0.5 mg/dose (2 mg/3 mL) pen |
| Dulaglutide | Heart attack and coronary artery disease, Type 2 diabetes | No current entry | none listed | $487.57 per mL 0.75 mg/0.5 mL pen |
| Exenatide | Type 2 diabetes | No current entry | 1 labeler | $300.17 per mL 10 mcg dose pen injection |
| Insulin glargine and lixisenatide | Type 2 diabetes | No current entry | none listed | $57.06 per mL 100 unit-33 mcg/mL pen |
| Insulin glargine | Type 2 diabetes | A presentation being discontinued | none listed | $2.90 per mL 100 pen |
| Insulin aspart | Type 2 diabetes | No current entry | none listed | $6.95 per mL 100 unit/mL vial |
| Insulin lispro | Type 2 diabetes | A presentation being discontinued | none listed | $10.19 per mL 100 unit/mL kwikpen |
| Insulin human | Type 2 diabetes | No current entry | none listed | $4.26 per mL 70-30 vial |
| Insulin degludec | Type 2 diabetes | No current entry | none listed | $11.39 per mL 100 unit/mL pen |
| Pramlintide | Type 2 diabetes | A presentation being discontinued | none listed | n/a |
| Insulin detemir | Type 2 diabetes | No current entry | none listed | n/a |
Source: FDA drug labels, FDA Drug Shortage Database, NDC Directory, CMS NADAC of October 7, 2026 (FDA files October 8, 2026)
What next?
- Every shortage now
- medicines by presentations in shortage